/
Other
Pediatric
31
Pipeline Programs↗
33
Active Trials↗
56
Companies Involved↗
Pediatric is a moderately active landscape with 31 programs across 56 companies. The most active players are AstraZeneca, CSL Behring, GSK. 14 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical7
Phase 28
Phase 314
Approved
No programs
Analysis
Modality Breakdown
72%
Small molecule
21 of 29 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 29 classified programs, each share of the total. Modality classified for 100% of 31 pipeline programs.
Analysis
Trial Status
261
clinical trials
Completed180 · 69%
Terminated26 · 10%
Recruiting19 · 7%
Unknown status13 · 5%
Withdrawn9 · 3%
Active, not recruiting8 · 3%
Other6 · 2%
Clinical Trials
Trial Activity
261 trials
Psyllium in Pediatric IBS
Recruiting·—·Phase 2·NCT06639984·110 enrolled
GD2-CAR T Cells for Pediatric Brain Tumours
Recruiting·—·Phase 1·NCT05298995·54 enrolled
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
Recruiting·—·Phase 4·NCT02044497·68 enrolled
Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2/3·NCT06882057·3,000 enrolled
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 3·NCT07152041·150 enrolled
Page 1 of 18
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)